grant
Risk and Resilience, Clinical presentation, and Biomarker Profiles of Chronic Traumatic Encephalopathy and Related Dementias: The DIAGNOSE CTE Research Project II
Organization BOSTON UNIVERSITY MEDICAL CAMPUSLocation BOSTON, UNITED STATESPosted 15 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AD dementiaAD related dementiaADRDAccelerationAfrican AmericanAfro AmericanAfroamericanAgeAgreementAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimers DementiaAmentiaAmericanAmyloidAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid SubstanceAmyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAntigenic DeterminantsAnxietyArizonaAstroproteinAtrophicAtrophyAutopsyAwardAβB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2Binding DeterminantsBiological MarkersBlackBlack raceBloodBlood PlasmaBlood Reticuloendothelial SystemBlood VesselsBrainBrain Nervous SystemClinicalCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCommunitiesConsensusCross Sectional AnalysisCross-Sectional AnalysesCross-Sectional StudiesCross-Sectional SurveyDataData SetDegenerative Neurologic DisordersDementiaDetectionDevelopmentDiagnosisDiagnostics ResearchDiseaseDisease Frequency SurveysDisorderDisturbance in cognitionEncephalonEnrollmentEpitopesEvaluationExaminations and DiagnosesExposure toFTPFootballFrequenciesFunctional MRIFunctional Magnetic Resonance ImagingFundingGFA-ProteinGFAPGeneralized GrowthGlial Fibrillary Acid ProteinGlial Fibrillary Acidic ProteinGlial Intermediate Filament ProteinGoalsGroups at riskGrowthHPGFHeadHepatocyte-Stimulating FactorHomeHybridoma Growth FactorIFN-beta 2IFNB2IL-6IL6 ProteinImpaired cognitionInterleukin-6KnowledgeLengthLifeLiquid substanceLong-term cohortLongitudinal StudiesLongitudinal cohortMGI-2MR ImagingMR TomographyMRIMRIsMT-bound tauMagnetic Resonance ImagingManufactured footballMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMemoryMental DepressionMyeloid Differentiation-Inducing ProteinNINDSNMR ImagingNMR TomographyNational Institute of Neurological Diseases and StrokeNational Institute of Neurological Disorders and StrokeNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuron DegenerationNeuronsNewly DiagnosedNuclear Magnetic Resonance ImagingOutcomePETPET ScanPET imagingPETSCANPETTParticipantPathologicPathologyPatientsPatternPeople at riskPersonsPersons at riskPhenotypePlasmaPlasma SerumPlasmacytoma Growth FactorPlayPopulations at RiskPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPreventionPrimary Senile Degenerative DementiaProbabilityPrognosisPublishingR-Series Research ProjectsR01 MechanismR01 ProgramRaceRacesRad.-PETResearchResearch GrantsResearch Project GrantsResearch ProjectsResearch ResourcesResourcesReticuloendothelial System, Serum, PlasmaRiskRisk FactorsSeptum PellucidumSeveritiesSouth TexasSpecificitySymptomsSyndromeTestingTissue GrowthTracerTraumatic encephalopathyVisitZeugmatographya beta peptideabetaagesamyloid betaamyloid-b proteinbeta amyloid fibrilbio-markersbiologic markerbiomarkerbiomarker validationbrain septum pellucidumchronic traumatic encephalopathycingulate cortexclinical examclinical examinationcognitive controlcognitive dysfunctioncognitive losscohortcollegecollegiatecollision sportscontact sportsdaily functioningdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdementia riskdepressiondesigndesigningdevelopmentaldiagnostic criteriadisease diagnosisenrollexecutive controlexecutive functionfMRIfluidformycin 5'-triphosphateformycin A 5'-triphosphateformycin triphosphatehead impacthigh riskhomeshypoperfusioninjury to the vasculatureinsightinterferon beta 2life spanlifespanliquidlong-term studylongitudinal outcome studiesmalemarker validationmedial temporal areamedial temporal lobemesial temporal areamesial temporal lobemicrotubule bound taumicrotubule-bound taunecropsyneural degenerationneural inflammationneurobehavioralneurodegenerationneurodegenerativeneurodegenerative illnessneuroinflammationneuroinflammatoryneurological degenerationneuronalneuronal degenerationneuropathologicneuropathologicalneuropathologyneuropsychiatricneuropsychiatryontogenyp-taup-τphospho-tauphospho-τphosphorylated taupositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypost-translational modification of taupostmortemposttranslational modification of tauprimary degenerative dementiaracialracial backgroundracial originrecruitresilienceresilience factorresiliency factorresilientretention rateretention strategyrisk factor for dementiarisk for dementiasenile dementia of the Alzheimer typesexsocial health determinantssoluble amyloid precursor proteinsubstantia albatautau Proteinstau factortau phosphorylationtau posttranslational modificationtau-1treatment trialuptakevalidation studiesvascularvascular injurywhite matterwhite matter injuryτ Proteinsτ phosphorylation♂
Description preview
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease diagnosed postmortem in people
exposed to repetitive head impacts (RHI) from football and other contact sports. NINDS consensus research
diagnostic criteria for the clinical syndrome of CTE, known as traumatic encephalopathy syndrome (TES), were
published in 2021. However, we…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click